Equities research analysts at Morgan Stanley initiated coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) in a report issued on Tuesday, Marketbeat reports. The brokerage set an “overweight” rating and a $25.00 price target on the stock. Morgan Stanley’s price objective would suggest a potential upside of 61.81% from the company’s previous close.
Separately, Stifel Nicolaus started coverage on Contineum Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $29.00 price objective on the stock.
Check Out Our Latest Report on Contineum Therapeutics
Contineum Therapeutics Trading Down 1.0 %
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Featured Stories
- Five stocks we like better than Contineum Therapeutics
- Short Selling: How to Short a Stock
- AMD is Down 35%. Now is the Time to Buy the Dip
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Amazon Stands Tall: New Highs Are in Sight
- What is a Bond Market Holiday? How to Invest and Trade
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
